This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...